跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NL-OMON53927
NL-OMON53927尚未招募不适用

A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors - 1403-0002: BI907828 with ezabenlimab and BI754111 in solid tumors

Boehringer Ingelheim0 个研究点目标入组 4 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
4
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99（—）

入选标准

  • •1. Provision of signed and dated, written informed consent form ICF in
  • •accordance with ICH-GCP and local legislation prior to any trial-specific
  • •procedures, sampling, or analyses.
  • •2. Male or female >=18 years old at the time of signature of the ICF.
  • •3. ECOG performance status of 0 or 1.
  • •4. Life expectancy of at least 12 weeks after the start of the treatment
  • •according to the Investigator*s judgement.
  • •5. Patients with radiologically documented disease progression or relapse
  • •during or after all standard of care treatments. Patients who are not eligible
  • •to receive standard of care treatments, and for whom no proven treatments
  • •exist, are eligible.
  • •6. Previous treatment with an anti-PD-1/PD-L1 mAb is allowed as long as the
  • •last administration of the anti-PD-1/PD-L1 mAb on the previous treatment
  • •occurred a minimum of 28 days prior to the first administration of study
  • •7. Patient must be willing to participate in the blood sampling for the PK, PD,
  • •and tumor mutation analysis.
  • •8. Adequate organ function defined as all of the following (all screening labs
  • •should be performed locally within 10 days of treatment initiation):
  • •Absolute neutrophil count >=1.5 x 10^9/L (or >= 1.5×10^3/µL or >= 1500/mm^3)
  • •Platelets >=100 x 10^9/L (or >= 100×10^3/µL or >= 100×10^3/mm^3)
  • •Hemoglobin >=8.5 g/dL or >=5.3 mmol/L (red blood cell transfusion allowed to meet
  • •eligibility criteria) or >= 85 g/L
  • •Total bilirubin <= 1.5 times the upper limit of normal (ULN), (patients with
  • •Gilbert*s syndrome, total bilirubin must be <=3 x ULN)
  • •AST and ALT <=2.5 x ULN OR <=5 x ULN for patients with liver metastases
  • •Creatinine <=1.5 x ULN
  • •Patients may enter if creatinine is >1.5 x ULN and estimated glomerular
  • •filtration rate (eGFR) >50 mL/min (assessed by Chronic Kidney Disease
  • •Epidemiology [CKDEPI] Collaboration equation); confirmation of eGFR is only
  • •required when creatinine is >1.5 X ULN
  • •International Normalised Ratio (INR) or Prothrombin Time (PT). Activated
  • •Partial Thromboplastin Time (aPTT) <=1.5 x institutional ULN. Patients taking
  • •low dose warfarin must have their INR
  • •followed closely and according to institutional guidelines.
  • •9. Women of childbearing potential (WOCBP), and men able to father a child must
  • •be ready and able to use two medically acceptable methods of birth control per
  • •ICH M3 (R2) that result in a low failure rate of less than 1% per year when
  • •used consistently and correctly beginning at screening, during trial
  • •participation and until certain time has passed after the last administration
  • •of trial medication:
  • •- Women: 6 months and 12 days after end of BI 907828; 6 months after end of
  • •ezabenlimab.
  • •- Men: 102 days after end of BI 907828; 6 months after end of ezabenlimab.
  • •A list of contraception methods meeting these criteria is provided in the
  • •patient information.
  • •Inclusion criteria 10-14 are only applicable to Phase I a.
  • •The following inclusion criteria are only applicable to Phase I b:
  • •15. At least one target lesion that can be accurately measured per RECIST 1.1.
  • •In patients who only have one target lesion, the baseline imaging must be
  • •performed at least two weeks after any biopsy of the target lesion.
  • 另有 3 项未显示

排除标准

  • •Patients must not enter the trial if any of the following exclusion criteria
  • •are fulfilled:
  • •1. Previous administration of BI 907828 or any other MDM2-p53 or MDMX
  • •(MDM4)-p53 antagonist.
  • •2. In Phase Ib (expansion phase) and Phase Ia expansion cohort only: a
  • •documented aminoacid altering mutation in TP53 occurring in the patient*s tumor.
  • •3. Symptomatic brain metastases.
  • •Note: Patients with previously treated brain metastases may participate but
  • •treated lesions should not be used as target lesions.
  • •4. Exclusion criterion 4 is not applicable for patients enrolled after protocol
  • •version 4 is approved.
  • •5. Active bleeding, significant risk of haemorrhage (e.g. previous severe
  • •gastrointestinal bleeding, previous haemorrhagic stroke at any time), or
  • •current bleeding disorder (e.g. haemophilia, von Willebrand disease).
  • •6. Major surgery (major according to the Investigator*s assessment) performed
  • •within 12 weeks prior to start of study treatment or planned within 12 months
  • •after screening (e.g. hip replacement).
  • •7. Any other documented active or suspected malignancy or history of malignancy
  • •within 3 years prior to screening, except appropriately treated basal cell
  • •carcinoma of the skin or in situ carcinoma of uterine cervix, or other local
  • •tumors considered cured by local treatment.
  • •8. Patients who must or wish to continue the intake of restricted medications
  • •(see Section 4.2.2.1) or any drug considered likely to interfere with the safe
  • •conduct of the trial.
  • •9. Currently enrolled in another investigational device or drug trial, or less
  • •than 4 weeks since receiving other investigational treatments. Patients who are
  • •in follow-up/observation for another clinical trial are eligible.
  • •10. Exclusion criterion 10 is not applicable for patients enrolled after
  • •protocol version 4 is approved.
  • •11. Patients who have not recovered from all clinically significant adverse
  • •events from their most recent therapy or intervention prior to study enrolment.
  • •12. Known history of human immunodeficiency virus (HIV) infection.
  • •13. Any of the following known laboratory evidence of hepatitis virus infection:
  • •o Positive results of hepatitis B surface (HBs) antigen
  • •o Presence of HBc antibody together with HBV-DNA
  • •o Presence of hepatitis C RNA
  • •14. Known hypersensitivity to the trial drugs or their excipients.
  • •15. Serious concomitant disease or medical condition affecting compliance with
  • •trial requirements or which are considered relevant for the evaluation of the
  • •efficacy or safety of the trial drug, such as neurologic, psychiatric,
  • •infectious disease or active ulcers (gastro-intestinal tract, skin) or
  • •laboratory abnormality that may increase the risk associated with trial
  • •participation or trial drug administration, and in the judgment of the
  • •Investigator, would make the patient inappropriate for entry into the trial.
  • •16. Chronic alcohol or drug abuse or any condition that, in the Investigator*s
  • •opinion, makes them an unreliable trial patient or unlikely to complete the
  • •17. Women who are pregnant, nursing, or who plan to become pregnant while in
  • •the trial; female patients who do not agree to the interruption of breast
  • •feeding from the start of study treatment until 6 months and 12 days after last
  • •dose of study treatment.
  • 另有 1 项未显示

研究者

相似试验

招募中
1 期
A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 in combination with BI 754091 (ezabenlimab)advanced solid tumor
JPRN-jRCT2080224759Boehringer Ingelheim170
招募中
1 期
A phase I study of ROSE12 alone and in combination with other anti-tumor agents in patients with solid tumorssolid tumor
JPRN-jRCT2031230072Ajari Ifode219
招募中
不适用
A Phase Ia/Ib Open Label, Dose-Escalation study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors.
NL-OMON55424Hoffmann-La Roche28
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCon-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-002382-19-PLPDC*line Pharma SAS64
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCon-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-002382-19-DEPDC*line Pharma SAS64